Targeted Oncology19h
Off-the-Shelf CAR-T Therapy P-BCMA-ALLO1 Shows Strong Activity in R/R Myeloma
The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...
Fierce Biotech21h
Allogene’s phase 1 lymphoma data show CAR-T could ‘leapfrog’ competition: analysts
Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...